

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Strongid-P Oral Paste 439 mg/g

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each g contains:

Active substances:

Pyrantel Embonate 439 mg

Excipients:

Qualitative composition of excipients and other constituents
Polysorbate 80
Methyl Hydroxybenzoate
Propyl Hydroxybenzoate
Sorbitol Solution 70% w/w (non-crystallising)
Sodium Alginate
Water purified

A smooth, pale yellow to buff paste.

3. CLINICAL INFORMATION

3.1 Target species

Horses, ponies, donkeys and foals over four weeks of age.

3.2 Indications for use for each target species

A broad spectrum anthelmintic for use in horses and donkeys for the control and treatment of adult infections of large and small strongyles, *Oxyuris*, *Parascaris* and *Anoplocephala perfoliata*.

Effective against benzimidazole resistant strains of small strongyles.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintics belonging to another pharmacological class and having a different mode of action should be used.

Resistance to pyrantel has been reported in cyathostomes in horses (also widespread in the US and Canada). Therefore the use of this product should be based on a local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

3.5 Special precautions for use

Special precautions for safe use in the target species:

The same oral syringe should only be used to dose two animals if they are both healthy and are either running together or are on the same premises and in direct contact with each other.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Avoid contact with skin. Wash hands and any other parts of the body which come into contact with the product.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Horses, ponies, donkeys, foals:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Colic ¹ , Intestinal impaction ²
---	--

¹May be seen within 30 minutes of treatment.

²May occur in foals infected with high numbers of *Parascaris equorum*.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian,

to either the marketing authorisation holder or the national competent authority via the national reporting system. See the label for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The veterinary medicinal product is specifically recommended for use in mares which may be pregnant and/or lactating.

3.8 Interaction with other medicinal products and other forms of interaction

Combined administration of pyrantel and levamisole or piperazine is not recommended.

3.9 Administration routes and dosage

Oral use.

Administration:

The veterinary medicinal product is recommended for direct oral administration in horses, ponies, donkeys and foals over four weeks of age. It is not necessary to withhold any feed prior to administration. The following method of administration is recommended:

1. Position the locking ring over the appropriate mark on the plunger.
2. Remove the cap from the nozzle.
3. The paste is best deposited on the upper surface of the tongue. Introduce the nozzle end of the oral syringe at the corner of the mouth. Direct the oral syringe backwards and depress the plunger to deposit the paste onto tongue. Providing the paste is given in this way it is unlikely that any rejection will occur. Raising the head by a hand under the chin sometimes helps with swallowing.

Dosage:

For the control and treatment of strongyles *Oxyuris* and *Parascaris* but excluding *Anoplocephala* (tapeworm), the veterinary medicinal product should be used at a dose rate of 19 mg pyrantel embonate per kg bodyweight.

Bodyweight range	Dose – contents of	Dose of pyrantel embonate
Up to 150kg	¼ oral syringe	2.85g
151 – 300kg	½ oral syringe	5.70g
301 – 450kg	¾ oral syringe	8.55g
451 – 600kg	Full oral syringe	11.40g

Note: Position locking ring over appropriate mark on plunger.

Dosage: For the control and treatment of tapeworms: the veterinary medicinal product should be used at a dose rate of 38 mg pyrantel embonate per kg bodyweight, that is twice the dose rate for strongyles.

To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked.

Inappropriate use of anthelmintics may increase resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on professional advice and take into account current best practice recommendations for parasite control.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

The veterinary medicinal product has an extremely wide safety margin and overdosage should not produce any adverse reactions.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Meat and offal: zero days.

4. PHARMACOLOGICAL IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QP52AF02

5. PHARMACEUTICAL PARTICULARS

Pyrantel embonate is a member of the tetrahydropyrimidine class of anthelmintic compounds. It possesses broad spectrum activity against the major gastro-intestinal helminths of animals and man.

It is effective against the following gastro-intestinal helminths of foals, adult horses and donkeys.

Large and small strongyles (including benzimidazole-resistant strains of small strongyles)

Oxyuris equi

Parascaris equorum

Anoplocephala perfoliata

Pyrantel acts as a potent agonist at acetylcholine (ACh) receptors on muscle cells of nematodes leading to neuromuscular block characteristic of depolarising agents.

This results in a prolonged spastic paralysis of the worm and expulsion from the host.

Pyrantel embonate is relatively insoluble and poorly absorbed from the gut. Its activity is confined to parasites dwelling within the gut lumen. The small amount of

pyrantel absorbed into the circulation is rapidly metabolised and the drug metabolites have no toxic potential.

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 2 months.

5.3 Special precautions for storage

Protect from direct sunlight.
Do not store above 25°C.
Store in a tightly closed original container.

5.4 Nature and composition of immediate packaging

Pack size: 26g
Container: Metering syringe with high density polyethylene barrel, plunger and locking ring.
Closure: Low density polyethylene piston and endcap.
Content: Pale yellow to buff coloured oral paste.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Elanco GmbH

7. MARKETING AUTHORISATION NUMBERS

Vm 52127/5081
Vm 52127/3016

8. DATE OF FIRST AUTHORISATION

23 May 1994

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

November 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall

Approved: 24 February 2026